Bisphosphonate use and related pharmaceutical issues II
UNLABELLED: Bisphosphonates have basic role in decreasing progression of malignant bone processes as well as in the prevention and therapy of osteoporosis. Use of bisphosphonates is common in Hungary since 20 years. In the past decade their reimbursement has been changed several times, the use of generics decreased the price of bisphosphonates. In this paper we analyze the consumption of prescribed bisphosphonates in Hungary.
DATA: Prescription data of the National Health Insurance Fund of Hungary.
METHOD: We analysed the prescribed bisphosphonates between 2006-2014. We examined the type and amount of bisphosphonates used by years. After identifying therapy areas of use, we calculated the years of therapy from the DOT data. From this data we estimated the mean bisphosphonate therapy costs and costs falling for the patients. Changes in the reimbursement system regarding these medications was analysed.
RESULTS: Bisphosphonate years of therapy was decreasing in osteoporosis over the 9 years examined. In oncology bisphosphonate use shows stability in drug consumption. In both therapeutic areas the proportion in therapy choice of specific bisphosphonates has changed. Bisphosphonate reimbursement costs paid by the Hungarian reimbursement system was approx. 8 billion HUF in osteoporosis and 4,7 billion HUF in oncology in 2006. Changes of the reimbursement strategy, the compulsory generic use and decreasing consumption in osteoporosis has significantly reduced the overall costs by 2014.
CONCLUSION: According to our results bisphpsphonate use in oncology is moderate in Hungary, a decreasing consumption can be detected in osteoporosis, that is still expected to decrease. The use of generics reduced bisphosphonate therapy costs and also overall health care costs. In osteoporosis patients cost have substantially lowered.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
Acta pharmaceutica Hungarica - 86(2016), 1 vom: 10., Seite 23-34 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A biszfoszfonátok alkalmazásának gyakorlata és aktuális gyógyszerészeti vonatkozásai II |
|---|
| Beteiligte Personen: |
Veszelyné Kotan, Edit [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 19.07.2016 Date Revised 10.12.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM26134384X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM26134384X | ||
| 003 | DE-627 | ||
| 005 | 20231224195343.0 | ||
| 007 | tu | ||
| 008 | 231224s2016 xx ||||| 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n0871.xml |
| 035 | |a (DE-627)NLM26134384X | ||
| 035 | |a (NLM)27295874 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Veszelyné Kotan, Edit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bisphosphonate use and related pharmaceutical issues II |
| 246 | 3 | 3 | |a A biszfoszfonátok alkalmazásának gyakorlata és aktuális gyógyszerészeti vonatkozásai II |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2016 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a UNLABELLED: Bisphosphonates have basic role in decreasing progression of malignant bone processes as well as in the prevention and therapy of osteoporosis. Use of bisphosphonates is common in Hungary since 20 years. In the past decade their reimbursement has been changed several times, the use of generics decreased the price of bisphosphonates. In this paper we analyze the consumption of prescribed bisphosphonates in Hungary | ||
| 520 | |a DATA: Prescription data of the National Health Insurance Fund of Hungary | ||
| 520 | |a METHOD: We analysed the prescribed bisphosphonates between 2006-2014. We examined the type and amount of bisphosphonates used by years. After identifying therapy areas of use, we calculated the years of therapy from the DOT data. From this data we estimated the mean bisphosphonate therapy costs and costs falling for the patients. Changes in the reimbursement system regarding these medications was analysed | ||
| 520 | |a RESULTS: Bisphosphonate years of therapy was decreasing in osteoporosis over the 9 years examined. In oncology bisphosphonate use shows stability in drug consumption. In both therapeutic areas the proportion in therapy choice of specific bisphosphonates has changed. Bisphosphonate reimbursement costs paid by the Hungarian reimbursement system was approx. 8 billion HUF in osteoporosis and 4,7 billion HUF in oncology in 2006. Changes of the reimbursement strategy, the compulsory generic use and decreasing consumption in osteoporosis has significantly reduced the overall costs by 2014 | ||
| 520 | |a CONCLUSION: According to our results bisphpsphonate use in oncology is moderate in Hungary, a decreasing consumption can be detected in osteoporosis, that is still expected to decrease. The use of generics reduced bisphosphonate therapy costs and also overall health care costs. In osteoporosis patients cost have substantially lowered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Bone Density Conservation Agents |2 NLM | |
| 650 | 7 | |a Diphosphonates |2 NLM | |
| 650 | 7 | |a Drugs, Generic |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Clodronic Acid |2 NLM | |
| 650 | 7 | |a 0813BZ6866 |2 NLM | |
| 650 | 7 | |a Zoledronic Acid |2 NLM | |
| 650 | 7 | |a 6XC1PAD3KF |2 NLM | |
| 650 | 7 | |a Risedronic Acid |2 NLM | |
| 650 | 7 | |a KM2Z91756Z |2 NLM | |
| 650 | 7 | |a Pamidronate |2 NLM | |
| 650 | 7 | |a OYY3447OMC |2 NLM | |
| 650 | 7 | |a Ibandronic Acid |2 NLM | |
| 650 | 7 | |a UMD7G2653W |2 NLM | |
| 650 | 7 | |a Alendronate |2 NLM | |
| 650 | 7 | |a X1J18R4W8P |2 NLM | |
| 700 | 1 | |a Mészáros, Ágnes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica Hungarica |d 1965 |g 86(2016), 1 vom: 10., Seite 23-34 |w (DE-627)NLM000024872 |x 0001-6659 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2016 |g number:1 |g day:10 |g pages:23-34 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2016 |e 1 |b 10 |h 23-34 | ||